Efficient infection of tumor endothelial cells by a capsid-modified adenovirus

Gene Therapy

Volumn 13, Issue 1, 2006, Pages 52-59

  Shinozaki, K ^a   Suominen, E ^b   Carrick, F ^a   Sauter, B ^a   Kahari V M ^b   Lieber, A ^c   Woo, S L C ^a   Savontaus, Mikko ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer treatment; Endothelial targeting; Hybrid adenovirus; Tumor vasculature

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CD31 ANTIGEN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; HEPATIC ARTERY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LIVER PARENCHYMA; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTYPE; TOXICITY TESTING; TUMOR CELL; TUMOR VASCULARIZATION; UMBILICAL VEIN; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS HYBRID;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIGENS, CD31; BIOLOGICAL MARKERS; CAPSID PROTEINS; CARCINOMA, HEPATOCELLULAR; ENDOTHELIAL CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MODELS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ADENOVIRIDAE; ANIMALIA; MIRIDAE;

EID: 29244465049     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302598     Document Type: Article

References (44)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
2. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404-2407.
3. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Therapy 2003; 10: 647-656.
4. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933-946.
5. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (review). Int J Oncol 2002; 21: 1161-1174.
6. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
7. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy 1999; 6: 1520-1535.
8. Tomko RP, Xu R, Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
9. Wickham TJ, Tzeng E, Shears II LL, Roelvink PW, Li Y, Lee GM et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
10. Merrick AF, Shewring LD, Sawyer GJ, Gustafsson KT, Fabre JW. Comparison of adenovirus gene transfer to vascular endothelial cells in cell culture, organ culture, and in vivo. Transplantation 1996; 62: 1085-1089.
11. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62: 1063-1068.
12. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70: 6831-6838.
13. Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001; 3: 882-891.
14. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Therapy 2001; 8: 341-348.
15. Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow GR et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
16. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001; 75: 11284-11291.
17. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, Vigne E et al. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 2003; 8: 485-494.
18. Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, Hayakawa T et al. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 2003; 77: 13062-13072.
19. Akiyama M, Thorne S, Kirn D, Roelvink PW, Einfeld DA, King CR et al. Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol Ther 2004; 9: 218-230.
20. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412.
21. Roelvink PW et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
22. Stevenson SC, Rollence M, White B, Weaver L, McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995; 69: 2850-2857.
23. Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166: 5236-5244.
24. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-458.
25. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
26. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: Fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996; 70: 2116-2123.
27. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D et al. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 2001; 75: 3335-3342.
28. Chillon M, Bosch A, Zabner J, Law L, Armentano D, Welsh MJ et al. Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J Virol 1999; 73: 2537-2540.
29. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812-2816.
30. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-550.
31. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A et al. Selective targeted delivery of TNFα to tumor blood vessels. Blood 2003; 102: 4384-4392.
32. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20: 264-269.
33. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380.
34. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-1038.
35. Savontaus MJ, Sauter BV, Huang TG, Woo SL. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Therapy 2002; 9: 972-979.
36. Gordon EM, Chen ZH, Liu L, Whitley M, Liu L, Wei D et al. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 2001; 12: 193-204.
37. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14: 1193-1206.
38. Sakurai F, Mizoguchi H, Yamaguchi T, Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003; 8: 813-821.
39. Biermann V, Volpers C, Hussmann S, Stock A, Kewes H, Schiedner G et al. Targeting of high-capacity adenoviral vectors. Hum Gene Ther 2001; 12: 1757-1769.
40. Mead R, Hinchliffe SJ, Morgan BP. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology 1999; 98: 137-143.
41. Elliott WL, Roberts BJ, Howard CT, Leopold III WR. Chemotherapy with
42. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 1997; 181: 207-212.
43. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
44. Bautista DS, Hitt M, McGrory J, Graham FL. Isolation and characterization of insertion mutants in E1A of adenovirus type 5. Virology 1991; 182: 578-596.